Topic: Discovery of biomarkers, precision medicine and immune oncology

A special issue of Journal of Cancer Metastasis and Treatment  (Print ISSN:2394-4722; Online ISSN:2454-2857).

Deadline for manuscript submissions: 31 Dec 2018

Share This Special Issue

Guest Editor(s)

  • Prof. Bingliang Fang
    Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center

    Website | E-mail

Special Issue Introduction:

With advances of genomics, transcriptomics, proteomics and metabolomics, blooming data have been available for exploring molecular alternations in cancers. Many of these molecular alternations have been investigated as biomarkers for cancer diagnosis, prognosis and precision therapies. Indeed, the success of most targeted anticancer therapies, such as inhibitors for EGFR, ALK, BRAF, and PARP as cancer therapies rely on biomarker-directed precision therapy. This special issue contains several articles in the areas of discovery of biomarkers, precision medicine and immune oncology. It is now clear that cancers with the same origins, clinical stages, and histopathologic diagnoses can be highly heterogeneous in responses to targeted therapeutic agents and immune checkpoint therapies. Various clinical trials have been shown that only a subgroups of patients benefit from pathway targeted therapy and immune checkpoint therapies. The inability to identify patients likely to respond to a treatment is one of major challenges in the early stages of clinical trials of anticancer agents and in clinical practice with some approved anticancer agents. Thus, identification of biomarkers capable of predicting treatment responses is crucial for targeted therapies and immunotherapies of cancers. The articles in this special issues discuss and/or report recent advances in discoveries of biomarkers, precision medicine and immune oncology, including strategies, experimental approaches, technologies, and clinical validations and applications. I hope this issue will provide our readers helpful information about recent advances and achievements in this evolving field.

Keywords:

Target therapies, pathway targeted therapies, small molecular inhibitors, biomarkers, gene mutations, epigenetics, molecular signatures, treatment responses, patient stratification, clinical trials, biomarker-directed therapy, and immunotherapy, immune checkpoint inhibitors, metastasis, cancer stem cells, combinational therapy, precision therapies.

Submission Information:

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jcmtjournal.com/pages/view/author_instructions
For Online Submission, please login at https://mc03.manuscriptcentral.com/jcmt
Submission Deadline: 31 Dec 2018
Contacts: Alice Qian, Assistant Editor, editor002@jcmtjournal.com

 

Planned Papers

The following list shows the information of planned papers to this special issue. All the papers submitted to Journal of Cancer Metastasis and Treatment will go through a rigorous peer review. (Please note that the information below is provisional and may be subject to future change)

Type of paper: Review article
Tentative Title:  Impact of Tumor mutation burden in cancer immunotherapy: Crossroad of tumor biology and immune system
Authors: Yutaka Shio, Yuki Ozaki, Satoshi Muto, Naoyuki Okabe, Takeo Hasegawa, Suzuki Hiroyuki
Affiliation: Department of Chest Surgery, Fukushima Medical University
Possible Abstract:
Rapid progress in the fields both of molecular diagnosis and tumor immunology clearly changed cancer treatment. Profound understandings for tumor immunology contributed cancer immunotherapy mainly in using immune checkpoint inhibitors. On the other hand, clinical genomic analysis brought clinically meaningful effective molecular targeted therapy such as epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and so on. Recent accumulation of these successes make further evolution in tumor biology and immunology. Currently, we are able to apply next generation sequencing (NGS) to clinical use. Representatively, analyzing a tumor mutation burden (TMB) by whole exome sequencing and large cancer panel analysis could be an promising predictive biomarker. TMB is assumed to be closely correlated with tumor neo-antigen frequency and contribute to immune reactiveness of T cells to tumors. In this review, recent update of molecular analysis by using NGS and clinical significance of TMB in immunotherapy will be discussed.

Type of paper: Original article
Tentative Title: A pilot study of distinguishing basal cell carcinoma from normal human skin tissues using resonance Raman spectroscopy from key vibrational biomarkers
Authors: Cheng-hui Liu, Binlin Wu, Laura Sordillo, Chunyuan Zhang, Hugh Beckman, Lin Zhang, Zhe Pei, Lingyan Shi, and Robert R Alfano
Affiliation: Departments of Physics and Electrical Engineering, City University of New York, Institute for Ultrafast Spectroscopy and Lasers, New York, United States
Possible Abstract:
The use of 532 nm provides greater Raman signals from near resonance absorption bands of biomolecules in skin as compared with using an excitation NIR light source. The objectives of this study are to applying Visible Resonant Raman (VRR) spectroscopic technique to find the key molecules peak in VRR spectra fast and distinguish between basal cell carcinoma and healthy human skin using key vibrational biomarkers.
Visible Resonant Raman (VRR) spectroscopic technique offer great speed to measure Raman spectra it been undertaken in this study for basal cell carcinoma and normal human skin tissues using an excitation light source at a wavelength of 532nm. The use of 532 nm provides greater Raman signals from near resonance absorption bands of biomolecules as compared with using an excitation NIR light source.
In this study normal and basal cell carcinoma (BCC) human skin tissue samples were measured using VRR technique, revealing native biomarkers such as tryptophan, carotenoids, lipids and proteins. The VRR spectra from BCC skin cancer samples showed a strong enhancement in proteins including collagen type I combined with amide I and amino acids, and a decrease in carotenoids and lipids. These enhanced molecular fingerprints demonstrate a potential of VRR spectroscopic technique to be a label free molecular pathology method for human skin and other human diseases. A PCA-SVM statistical analysis method based on these molecular fingerprints was developed for differentiating BCC (cancer) from normal skin tissues, from limited sample data yielding a 93.0% diagnostic sensitivity, 100% specificity, and 94.5% accuracy compared with histopathology.

Type of paper: Review article
Tentative Title: Sensitive and specific detection of circulating tumor cells promotes precision medicine for cancer
Authors: Qinqin Huang, Wei Liu, Shi-Shang Guo, Xing-Zhong Zhao
Affiliation: Key Laboratory of Artificial Micro- and Nano-Structures of Ministry of Education, School of Physics and Technology, Wuhan University, Wuhan 430072, China.
Possible Abstract:
Circulating tumor cells (CTCs) have the potential to provide genetic information for dynamic and heterogeneous tumors, which would be useful for monitoring disease progression and developing personalized therapies. However, the isolation of CTCs for molecular analysis still remains a tremendous challenge due to their extreme rarity and phenotypic heterogeneity, which hinders the transformation of CTC into traditional clinical applications. In order to achieve clinically significant CTC detection, current methods developed using novel microfluidics and nanotechnology have been designed to achieve high sensitivity and specificity capture of CTCs. In this review, we discuss these developed devices for CTC capture and CTC molecular characterization for early diagnose and treatment decision to better manage these cancers clinically. In addition, the potential prognostic values of CTCs as treatment guidelines and that ultimately contribute to realize personalized treatment are also discussed.

Type of paper: Original Article
Tentative Title: Determination of cytokine regulated glycan expression by using molecular imprinted polymers (MIPs) targeting sialic acid
Authors: Llapastica K, Zhang Y, Shinde S, Sellergren B, El-Schich Z, Gjörloff Wingren A.
Affiliation: Biomedical Science, Health and society, Malmö University, Malmö, Sweden
Possible Abstract:
Cancer cells often have an increased amount of glycans, such as sialic acid (SA), on the cell surface, which normally play an important role in cell growth, proliferation and differentiation. In this study, SA expression is determined by fluorescent nanoprobes, molecular imprinted polymers, SA-MIPs. Inflammation and cytokine production are well known tumor promoters, modulating the cellular microenvironment. The recombinant cytokines IL-4, IL-6, IL-8 and a cocktail of cytokines collected from stimulated T leukemia Jurkat cells were used to induce in vitro inflammation in two cell lines, and thereafter analyzed with the use of SA-MIPs and flow cytometry. Both cell lines showed an increased level of sialic acid expression after treatment with IL-4 and with the cytokine cocktail, while treatment with IL-6 and IL-8 downregulated the sialic acid expression. This study shows that SA-MIPs can be an important tool in the investigation of overexpressed glycans in the tumor microenvironment.

Published Articles
    This special issue is now open for submission.
Journal of Cancer Metastasis and Treatment ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.